Actions
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
3
Neutral
7
Bullish
4
Bearish
21
Neutral
7
Bullish
18
Bearish
18
Neutral
0
Bullish
14
Bearish
18
Neutral
0
Bullish
14
Bearish
18
Neutral
0
Bullish
14
Bearish
18
Neutral
0
Bullish
14

View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Pharmaceuticals & Biotechnology
Biotechnology
3,089 Cr
Moderate Risk
17.3
39.5
1.8
1.9
419.80
247.10
Sales CAGR
Profit CAGR
ROE
ROCE

Advanced Enzyme Technologies Ltd (ADVENZYMES) is currently trading at 281.90 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Advanced Enzyme Technologies Limited manufactures and sells enzymes and enzyme-based solutions for human healthcare, animal healthcare, food processing, biocatalysis, and specialized manufacturing across Indian and international markets. Q2 FY27 revenue rose 16% year-on-year to INR2,145 million, while EBITDA increased 20% to INR721 million. EBITDA margin expanded to 34% from 33% a year earlier and 28% sequentially, despite elevated power, fuel, and raw-material costs, highlighting meaningful operating leverage and efficiency gains. Growth is broadening beyond the core human healthcare business. Animal Healthcare, Bio-Processing, and Specialized Manufacturing grew 37%, 43%, and 25% year-on-year respectively in Q2, while SciTech’s H1 revenue increased 32% and its EBITDA rose 144%, supported by better capacity utilization and a wider customer base. The United States remains subdued, but management sees early signs of recovery following recent industry engagement, R&D work, clinical studies, and technical publications. A meaningful turnaround could improve growth and margins, although its timing remains uncertain and existing US customers are not yet growing rapidly. The company completed a buyback of 2.41 million shares at an average INR289.09 per share. After additional October purchases, management indicated approximately INR610 crore of cash remained, excluding October internal accruals, providing substantial financial flexibility for capex, R&D, acquisitions, or shareholder returns.
Over the past 52 weeks, Advanced Enzyme Technologies Ltd has traded between a low of ₹247.10 and a high of ₹419.80. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Advanced Enzyme Technologies Ltd has a market capitalization of approximately 3,101.79. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Advanced Enzyme Technologies Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 17.41 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 3,101.79 Cr, Advanced Enzyme Technologies Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Advanced Enzyme Technologies Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Advanced Enzyme Technologies Ltd is 17.41. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Advanced Enzymes has not set a recovery date. Management said the turnaround could take one quarter, two quarters or longer, while also expecting improvement toward the year-end. It did not provide U.S.-specific revenue guidance.
Advanced Enzymes reported SciTech revenue of Rs 23.4 crore in Q2 FY27, compared with Rs 18.5 crore in Q2 FY26. The increase was Rs 4.9 crore. It separately reported Specialized Manufacturing segment revenue of Rs 23.1 crore for the quarter without reconciling the difference.
Advanced Enzymes reported consolidated Q2 FY27 revenue of Rs 214.5 crore. This was 16% higher than Rs 184.5 crore in Q2 FY26 and 12% above Rs 191.7 crore in Q1 FY27.
AETL estimates that it can address a $250 million probiotics market over the next five years. The company assigns a 14% growth rate to that estimate and identifies it as part of human nutrition.